Zura Bio (FRA:94E) Research & Development: €39.84 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:94E Zura Bio Ltd FRA:94E
25 GF Score
Price €4.58
View Full Analysis

What is Zura Bio Research & Development?

Zura Bio FRA:94E -1.29% 25 Research & Development is €39.84 Mil as of Mar. 2026. GuruFocus rates FRA:94E with a GF Score™ of 25/100.

Research & Development is the aggregate amount of research and development expenses during the year. Zura Bio's Research & Development for the three months ended in Mar. 2026 was €12.76 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €39.84 Mil.

Zura Bio  (FRA:94E) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zura Bio Research & Development Related Terms

Zura Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Zura Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zura Bio Research & Development Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24 Dec25
Research & Development
0.00 40.35 23.30 35.94

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.69 7.55 10.18 9.36 12.76
FRA:94E
25GF Score
Zura Bio Ltd FRA:94E
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zura Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €39.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €39.84 Mil mean?
Zura Bio (FRA:94E) has a Research & Development of €39.84 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zura Bio and its competitors.
Is Zura Bio's Research & Development too high?
Zura Bio's current Research & Development is €39.84 Mil. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Research & Development compare to ASMB and ARTV?
Zura Bio's Research & Development of €39.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zura Bio and its competitors. Zura Bio's current Research & Development is €39.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (FRA:94E) has a current Research & Development of €39.84 Mil. The current Research & Development is €39.84 Mil. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zura Bio (FRA:94E), the current Research & Development is €39.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zura Bio Business Description

Other Exchanges ZURA:USA
Address 1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score

Get the complete analysis for FRA:94E

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.58
Price